(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance of datopotamab deruxtecan in lung and breast cancers, as well as FLAURA2 data reinforcing Tagrisso as a therapy for EGFR-mutated lung cancer, DUO-E results highlighting the benefit of immunotherapy and PARP inhibitor combinations in endometrial cancer, and first Imfinzi data in gastric cancer from the MATTERHORN Phase III trial. The data presentations reflect AstraZeneca’s commitment to redefining cancer care and eliminating cancer as a cause of death.
(PRESS RELEASE) CAMBRIDGE, 12-Oct-2023 — /EuropaWire/ — AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, 20 to 24 October 2023.
Nearly 100 abstracts will feature 19 approved and potential new medicines from AstraZeneca including two late-breaking Presidential Symposia and 26 oral presentations.
Highlights include:
- TROPION-Lung01 Phase III trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC) (Presidential Symposium, Monday 23 October).
- TROPION-Breast01 Phase III trial of datopotamab deruxtecan in patients with previously treated inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer (Presidential Symposium, Monday 23 October).
- FLAURA2 Phase III trial of Tagrisso (osimertinib) plus chemotherapy in EGFR-mutated (EGFRm) advanced NSCLC including safety and central nervous system metastases outcomes. Results were recently presented from the progression-free survival (PFS) primary analysis.
- DUO-E Phase III trial of Imfinzi (durvalumab) plus platinum-based chemotherapy followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) as maintenance therapy in newly diagnosed advanced or recurrent endometrial cancer.
- MATTERHORN Phase III trial of Imfinzi plus neoadjuvant chemotherapy (before surgery) for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
- DESTINY-PanTumor02 Phase II trial of AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in previously treated HER2-expressing advanced solid tumours including PFS and overall survival (OS) data from the primary analysis.
- Three bispecifics: data from several presentations will highlight the Company’s robust clinical programme of novel immuno-oncology (IO) bispecific antibodies including data for volrustomig in advanced clear cell renal cell carcinoma (MEDI5752, targeting PD-1/CTLA-4), and data for rilvegostomig (AZD2936, targeting PD-1/TIGIT) and sabestomig (AZD7789, targeting PD-1/TIM3) in lung cancer.
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “At ESMO, we are building on the potential of our antibody drug conjugate portfolio with results from the TROPION-Lung01 and TROPION-Breast01 Phase III trials demonstrating the promise of datopotamab deruxtecan for patients across multiple cancer types in two back-to-back Presidential Symposia. These first pivotal data from our robust clinical programme are just the beginning for this TROP2-directed antibody drug conjugate, which we believe could replace conventional chemotherapy for many patients.”
Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Our key data at ESMO demonstrate our commitment to redefining cancer care across a growing number of tumour types with high unmet need. Across lung, breast, gynaecologic and gastrointestinal cancers, the first data will be presented from four different pivotal trials which will raise the bar for patients with multiple medicines from our industry-leading portfolio and highlight the power of novel combinations.”
Datopotamab deruxtecan takes centre stage with promising data in lung and breast cancers
A Presidential Symposium will highlight PFS data from the TROPION-Lung01 Phase III trial evaluating datopotamab deruxtecan in patients with previously treated advanced NSCLC. In July, datopotamab deruxtecan became the first antibody drug conjugate to demonstrate a statistically significant improvement in PFS and a trend in improvement for OS compared to docetaxel, the current standard-of-care chemotherapy. Additionally, a mini-oral presentation will feature initial results from the TROPION-Lung05 Phase II trial evaluating datopotamab deruxtecan in patients with heavily pretreated advanced NSCLC with actionable genomic mutations (AGA). There are currently no TROP2-directed antibody drug conjugates approved for the treatment of patients with lung cancer.
Another Presidential Symposium will showcase data from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy. In September, datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in PFS and a trend in improvement for OS compared to investigator’s choice of chemotherapy.
Lastly, a mini-oral presentation will highlight updated safety and efficacy results from the BEGONIA Phase Ib/II trial of datopotamab deruxtecan plus Imfinzi in patients with previously untreated unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC), including duration of response. Early data from the trial presented previously demonstrated promising clinical responses in this setting, regardless of PD-L1 expression (low and high tumours).
Imfinzi combinations enter new tumour types and continue delivering in lung and biliary tract cancers
A late-breaking oral presentation will feature PFS data from the DUO-E Phase III trial evaluating treatment with Imfinzi and chemotherapy followed by either Imfinzi plus Lynparza or Imfinzi alone as maintenance therapy in patients with newly diagnosed advanced or recurrent endometrial cancer. High-level results recently announced showed both regimens demonstrated a statistically significant and clinically meaningful improvement in PFS compared to standard-of-care chemotherapy alone, with greater clinical benefit observed with the combination of Imfinzi and Lynparza as maintenance treatment.
Another late-breaking oral presentation will highlight pathologic complete response (pCR) data from the MATTERHORN Phase III trial of Imfinzi added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant chemotherapy for patients with resectable, early-stage and locally advanced gastric and GEJ cancers versus neoadjuvant therapy alone. High-level interim results demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pCR. This is the first global Phase III trial of an immunotherapy and FLOT chemotherapy combination to demonstrate clinical benefit in this setting. The trial is continuing to assess the primary endpoint of event-free survival.
Also in gastrointestinal cancers, two poster presentations of new data from the TOPAZ-1 Phase III trial will further reinforce the benefit of Imfinzi plus chemotherapy as a 1st-line standard-of-care treatment for advanced biliary tract cancer. Results will be shared from an exploratory analysis of an extended cohort of TOPAZ-1 patients enrolled in China. Additionally, results will be shared from an exploratory analysis assessing the impact of prognostic or predictive factors of OS in the trial.
A late-breaking mini-oral presentation in lung cancer will report exploratory analyses from the AEGEAN Phase III trial of Imfinzi-based treatment before and after surgery in patients with resectable NSCLC, evaluating potential associations between circulating tumour DNA (ctDNA) and neoadjuvant treatment responses.
Extending the benefits of Enhertu across HER2-expressing tumours
New data from the DESTINY-PanTumor02 and DESTINY-PanTumor01 Phase II trials will underscore the potential of Enhertu for previously treated patients with HER2-expressing or HER2-mutated advanced solid tumours, respectively, who currently have no targeted treatment options.
A late-breaking mini-oral presentation of primary results from DESTINY-PanTumor02 will highlight efficacy and safety outcomes for Enhertu in patients with HER2-expressing solid tumours. In July, high-level primary analysis results showed Enhertu demonstrated clinically meaningful PFS and OS, as well as provided robust and durable tumour responses across multiple HER2-expressing solid tumours in the trial. Additionally, a poster presentation will share exploratory biomarker analyses of HER2 expression and gene amplification in tissue and baseline plasma ctDNA.
A further oral presentation will feature the first report of primary results from DESTINY-PanTumor01 in patients with solid tumours that have specific HER2-activating mutations.
A mini-oral presentation will feature post-hoc pooled efficacy and safety analyses of the DESTINY-Lung01 and DESTINY-Lung02 Phase II trials of Enhertu in patients with HER2-mutated metastatic NSCLC with and without brain metastases.
Several presentations will feature new data from the DESTINY-Breast clinical programme for Enhertu, including its efficacy in patients with brain metastases.
Progressing next-wave treatments including best-in-class bispecifics
Several presentations will share data from AstraZeneca’s portfolio of novel IO bispecific antibodies, underscoring the Company’s investment in a robust clinical programme for this next wave of IO therapy.
These include:
- A mini-oral presentation of data from a Phase Ib trial of volrustomig (MEDI5752), a PD-1/CTLA-4 bispecific antibody, in the 1st-line treatment of patients with advanced clear cell renal cell carcinoma.
- Another mini-oral presentation of safety and preliminary efficacy results from the Phase I/IIa first-in-human trial of sabestomig (AZD7789), a PD-1/TIM-3 bispecific antibody, in patients with Stages IIIb-IV NSCLC resistant to previous anti-PD(L)1 therapy.
- A poster presentation of data from the ARTEMIDE-01 Phase I trial assessing rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, in patients with advanced or metastatic NSCLC.
Collaboration in the scientific community is critical to improving outcomes for patients. AstraZeneca is collaborating with Daiichi Sankyo Company Limited to develop and commercialise Enhertu and datopotamab deruxtecan, and with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza both as a monotherapy and in combination with other potential medicines. Independently, the companies are developing Lynparza in combination with their respective PD-L1 and PD-1 medicines, Imfinzi and pembrolizumab, in a number of tumour types.
Key AstraZeneca presentations during ESMO 2023
Lead Author | Abstract Title | Presentation details (CEST) |
---|---|---|
Antibody drug conjugates | ||
Datopotamab deruxtecan | ||
Ahn, M (presented by Lisberg, A) | Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic
(adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01 |
Abstract #LBA12
Presidential 3 23 October 2023 04:42 PM |
Bardia, A | Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial | Abstract #LBA11
Presidential 3 23 October 2023 04:30 PM |
Paz-Ares, L | TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) | Abstract #1341MO
Mini oral session 1 – NSCLC, metastatic 21 October 2023 09:30 AM |
Schmid, P | Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study | Abstract #379MO
Mini oral session – Breast cancer, metastatic 22 October 2023 08:30 AM |
Enhertu | ||
Modi, S | Trastuzumab Deruxtecan (T-DXd) Versus Treatment of Physician’s Choice (TPC) in patients (pts) With HER2-Low Unresectable and/or Metastatic Breast Cancer (mBC): Updated Survival Results of the Randomized, Phase 3 DESTINY-Breast04 Study | Abstract #376O
Proffered Paper session – Breast cancer, metastatic 21 October 2023 10:25 AM |
Hurvitz, S | A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (Mbc) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, 02, and -03 | Abstract #377O
Proffered Paper session – Breast cancer, metastatic 21 October 2023 10:55 AM |
Li, B | Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase 2 DESTINY-PanTumor01 (DPT-01) study | Abstract #654O
Proffered Paper session – Developmental therapeutics 22 October 2023 09:20 AM |
Li, B | Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02 | Abstract #1321MO
Mini oral session 2 – NSCLC, metastatic 22 October 2023 0:9:05 AM |
Meric-Bernstam, F | Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study | Abstract #LBA34
Mini oral session – Developmental therapeutics 23 October 2023 04:40 PM |
Smit, E | Baseline Circulating Tumor DNA (ctDNA) Biomarker Analysis of Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Non–Small Cell Lung Cancer (NSCLC) Treated With Trastuzumab Deruxtecan (T-DXd) | Abstract #151P
e-Poster – Biomarkers (agnostic) 21 October 2023 |
Tsurutani, J | Subgroup Analysis of Patients (pts) With HER2-Low Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) at Baseline From DESTINY-Breast04, A Randomized Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) vs Treatment of Physicians Choice (TPC) | Abstract #388P
e-Poster – Breast cancer, metastatic 21 October 2023 |
AZD5335 | ||
Meric-Bernstam, F | FONTANA: A Phase 1/2a study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours | Abstract #819TiP
e-Poster – Gynaecological cancers 22 October 2023 |
Immuno-oncology | ||
Westin, S | Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial | Abstract #LBA41
Proffered Paper session 2 – Gynaecological cancers 21 October 2023 09:15 AM |
Janjigian, Y (presented by Al-Batran, S) | Pathological complete response to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy with or without durvalumab in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the phase 3, randomised, double-blind MATTERHORN study | Abstract #LBA73
Proffered Paper session 1 – Gastrointestinal tumours, upper digestive 20 October 2023 02:10 PM |
Garassino, M | Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6 | Abstract #LBA61
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 23 October 2023 03:20 PM |
Reck, M | Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase 3 AEGEAN trial | Abstract #LBA59
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 23 October 2023 03:00 PM |
Filippi, A | Durvalumab after radiotherapy (RT) in patients with unresectable Stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study | Abstract #LBA62
Mini oral session 2 – Non-metastatic NSCLC and other thoracic malignancies 23 October 2023 03:30 PM |
Besse, B | Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) with previous anti-PD-L(1) therapy | Abstract #1313MO
Mini oral session 1 – NSCLC, metastatic 21 October 2023 09:15 AM |
Voss, M | MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal carcinoma (aRCC) | Abstract #1883MO
Mini oral session – Genitourinary tumours, non-prostate 22 October 2023 11:25 AM |
Brandão, M | Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01 | Abstract #1446P
e-Poster – NSCLC, metastatic 23 October 2023 |
He, A | Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised Phase 3 TOPAZ-1 study | Abstract #102P
e-Poster – Biliary tract cancer, incl. cholangiocarcinoma 23 October 2023 |
Qin, S | Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: extension cohort of the Phase 3, randomised, double-blind, placebo-controlled, global TOPAZ-1 study | Abstract #98P
e-Poster – Biliary tract cancer, incl. cholangiocarcinoma 23 October 2023 |
Tumour drivers and resistance | ||
Jänne, P | Circulating tumour DNA (ctDNA) profiling in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC receiving osimertinib + chemotherapy vs osimertinib monotherapy: FLAURA2 | Abstract #LBA68
Mini oral session 1 – NSCLC, metastatic 21 October 2023 08:30 AM |
DNA damage response | ||
Mehra, N | Efficacy of Olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial | Abstract #1805P
e-Poster – Prostate cancer 22 October 2023 |
Notes
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Media Contact:
Tel: +44 (0)1223 344 800
email: global-mediateam@astrazeneca.com
SOURCE: AstraZeneca
MORE ON ASTRAZENECA, ETC.:
- Digi Communications N.V. announced that its Spanish subsidiary, Digi Spain Telecom S.L.U., has completed the first stage of selling a Fibre-to-the-Home (FTTH) network in 12 Spanish provinces
- Natural Cotton Color lancia la collezione "Calunga" a Milano
- Astor Asset Management 3 Ltd: Salinas Pliego Incumple Préstamo de $110 Millones USD y Viola Regulaciones Mexicanas
- Astor Asset Management 3 Ltd: Salinas Pliego Verstößt gegen Darlehensvertrag über 110 Mio. USD und Mexikanische Wertpapiergesetze
- ChargeEuropa zamyka rundę finansowania, której przewodził fundusz Shift4Good tym samym dokonując historycznej francuskiej inwestycji w polski sektor elektromobilności
- Strengthening EU Protections: Robert Szustkowski calls for safeguarding EU citizens’ rights to dignity
- Digi Communications NV announces the release of H1 2024 Financial Results
- Digi Communications N.V. announces that conditional stock options were granted to a director of the Company’s Romanian Subsidiary
- Digi Communications N.V. announces Investors Call for the presentation of the H1 2024 Financial Results
- Digi Communications N.V. announces the conclusion of a share purchase agreement by its subsidiary in Portugal
- Digi Communications N.V. Announces Rating Assigned by Fitch Ratings to Digi Communications N.V.
- Digi Communications N.V. announces significant agreements concluded by the Company’s subsidiaries in Spain
- SGW Global Appoints Telcomdis as the Official European Distributor for Motorola Nursery and Motorola Sound Products
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2023 financial year
- Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2023, as approved by the Company’s Ordinary General Shareholders’ Meetings from 18th May 2021 and 28th December 2022
- Digi Communications N.V. announces the granting of conditional stock options to Executive Directors of the Company based on the general shareholders’ meeting approval from 25 June 2024
- Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2023 Annual Report
- Czech Composer Tatiana Mikova Presents Her String Quartet ‘In Modo Lidico’ at Carnegie Hall
- SWIFTT: A Copernicus-based forest management tool to map, mitigate, and prevent the main threats to EU forests
- WickedBet Unveils Exciting Euro 2024 Promotion with Boosted Odds
- Museum of Unrest: a new space for activism, art and design
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by companies within Digi Group
- Digi Communications N.V. announces the agreements concluded by Digi Romania (formerly named RCS & RDS S.A.), the Romanian subsidiary of the Company
- Green Light for Henri Hotel, Restaurants and Shops in the “Alter Fischereihafen” (Old Fishing Port) in Cuxhaven, opening Summer 2026
- Digi Communications N.V. reports consolidated revenues and other income of EUR 447 million, adjusted EBITDA (excluding IFRS 16) of EUR 140 million for Q1 2024
- Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group
- Digi Communications N.V. Announces the convocation of the Company’s general shareholders meeting for 25 June 2024 for the approval of, among others, the 2023 Annual Report
- Digi Communications NV announces Investors Call for the presentation of the Q1 2024 Financial Results
- Digi Communications intends to propose to shareholders the distribution of dividends for the fiscal year 2023 at the upcoming General Meeting of Shareholders, which shall take place in June 2024
- Digi Communications N.V. announces the availability of the Romanian version of the 2023 Annual Report
- Digi Communications N.V. announces the availability of the 2023 Annual Report
- International Airlines Group adopts Airline Economics by Skailark ↗️
- BevZero Spain Enhances Sustainability Efforts with Installation of Solar Panels at Production Facility
- Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares
- BevZero South Africa Achieves FSSC 22000 Food Safety Certification
- Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million
- Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics
- driveMybox continues its international expansion: Hungary as a new strategic location
- Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget
- Digi Communications NV announces the release of the 2023 Preliminary Financial Results
- Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results
- Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София
- Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal
- Digi Communications N.V. Announces the release of the Financial Calendar for 2024
- Customer Data Platform Industry Attracts New Participants: CDP Institute Report
- eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir
- BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology
- Digi Communications N.V. announces share transaction made by a Non-Executive Director of the Company with class B shares
- Digi Spain Telecom, the subsidiary of Digi Communications NV in Spain, has concluded a spectrum transfer agreement for the purchase of spectrum licenses
- Эксперт по торговле акциями Сергей Левин запускает онлайн-мастер-класс по торговле сырьевыми товарами и хеджированию
- Digi Communications N.V. announces the conclusion by Company’s Portuguese subsidiary of a framework agreement for spectrum usage rights
- North Texas Couple Completes Dream Purchase of Ouray’s Iconic Beaumont Hotel
- Предприниматель и филантроп Михаил Пелег подчеркнул важность саммита ООН по Целям устойчивого развития 2023 года в Нью-Йорке
- Digi Communications NV announces the release of the Q3 2023 Financial Results
- IQ Biozoom Innovates Non-Invasive Self-Testing, Empowering People to Self-Monitor with Laboratory Precision at Home
- BevZero Introduces Energy Saving Tank Insulation System to Europe under name “BevClad”
- Motorvision Group reduces localization costs using AI dubbing thanks to partnering with Dubformer
- Digi Communications NV Announces Investors Call for the Q3 2023 Financial Results
- Jifiti Granted Electronic Money Institution (EMI) License in Europe
- Предприниматель Михаил Пелег выступил в защиту образования и грамотности на мероприятии ЮНЕСКО, посвящённом Международному дню грамотности
- VRG Components Welcomes New Austrian Independent Agent
- Digi Communications N.V. announces that Digi Spain Telecom S.L.U., its subsidiary in Spain, and abrdn plc have completed the first investment within the transaction having as subject matter the financing of the roll out of a Fibre-to-the-Home (“FTTH”) network in Andalusia, Spain
- Продюсер Михаил Пелег, как сообщается, работает над новым сериалом с участием крупной голливудской актрисы
- Double digit growth in global hospitality industry for Q4 2023
- ITC Deploys Traffic Management Solution in Peachtree Corners, Launches into United States Market
- Cyviz onthult nieuwe TEMPEST dynamische controlekamer in Benelux, Nederland
- EU-Funded CommuniCity Launches its Second Open Call
- Astrologia pode dar pistas sobre a separação de Sophie Turner e Joe Jonas
- La astrología puede señalar las razones de la separación de Sophie Turner y Joe Jonas
- Empowering Europe against infectious diseases: innovative framework to tackle climate-driven health risks
- Montachem International Enters Compostable Materials Market with Seaweed Resins Company Loliware
- Digi Communications N.V. announces that its Belgian affiliated companies are moving ahead with their operations
- Digi Communications N.V. announces the exercise of conditional share options by an executive director of the Company, for the year 2022, as approved by the Company’s Ordinary General Shareholders’ Meeting from 18 May 2021
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2022 financial year
- Digi Communications N.V. announces the availability of the 2022 Annual Report
- Digi Communications N.V. announces the general shareholders’ meeting resolutions from 18 August 2023 approving amongst others, the 2022 Annual Accounts
- Русские эмигранты усиливают призывы «Я хочу, чтобы вы жили» через искусство
- BevZero Introduces State-of-the-Art Mobile Flash Pasteurization Unit to Enhance Non-Alcoholic Beverage Stability at South Africa Facility
- Russian Emigrés Amplify Pleas of “I Want You to Live” through Art
- Digi Communications NV announces the release of H1 2023 Financial Results
- Digi Communications NV Announces Investors Call for the H1 2023 Financial Results
- Digi Communications N.V. announces the convocation of the Company’s general shareholders meeting for 18 August 2023 for the approval of, among others, the 2022 Annual Report
- “Art Is Our Weapon”: Artists in Exile Deploy Their Talents in Support of Peace, Justice for Ukraine
- Digi Communications N.V. announces the availability of the 2022 Annual Financial Report
- “AmsEindShuttle” nuevo servicio de transporte que conecta el aeropuerto de Eindhoven y Ámsterdam
- Un nuovo servizio navetta “AmsEindShuttle” collega l’aeroporto di Eindhoven ad Amsterdam
- Digi Communications N.V. announces the conclusion of an amendment agreement to the Facility Agreement dated 26 July 2021, by the Company’s Spanish subsidiary
- Digi Communications N.V. announces an amendment of the Company’s 2023 financial calendar
- iGulu F1: Brewing Evolution Unleashed
- Почему интерактивная «Карта мира» собрала ключевые антивоенные сообщества россиян по всему миру и становится для них важнейшим инструментом
- Hajj Minister meets EU ambassadors to Saudi Arabia
- Online Organizing Platform “Map of Peace” Emerges as Key Tool for Diaspora Activists
- Digi Communications N.V. announces that conditional stock options were granted to executive directors of the Company based on the general shareholders’ meeting approval from 18 May 2021
- Digi Communications N.V. announces the release of the Q1 2023 financial results
- AMBROSIA – A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE
- Digi Communications NV announces Investors Call for the Q1 2023 Financial Results presentation
- Digi Communications N.V. announces the amendment of the Company’s 2023 financial calendar
- Digi Communications N.V. announces the conclusion of two Facilities Agreements by the Company’s Romanian subsidiary
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by the Company’s Romanian subsidiary
- Patients as Partners Europe Returns to London and Announces Agenda Highlights
- GRETE PROJECT RESULTS PRESENTED TO TEXTILE INDUSTRY STAKEHOLDERS AT INTERNATIONAL CELLULOSE FIBRES CONFERENCE
- Digi Communications N.V. announces Digi Spain Telecom S.L.U., its subsidiary in Spain, entered into an investment agreement with abrdn to finance the roll out of a Fibre-to-the-Home (FTTH) network in Andalusia, Spain
- XSpline SPA / University of Linz (Austria): the first patient has been enrolled in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE)
- Franklin Junction Expands Host Kitchen® Network To Europe with Digital Food Hall Pioneer Casper
- Unihertz a dévoilé un nouveau smartphone distinctif, Luna, au MWC 2023 de Barcelone
- Unihertz Brachte ein Neues, Markantes Smartphone, Luna, auf dem MWC 2023 in Barcelona
- Editor's pick archive....